Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methods of utilizing baseline values for indirect response models.
Woo S, Pawaskar D, Jusko WJ. Woo S, et al. Among authors: pawaskar d. J Pharmacokinet Pharmacodyn. 2009 Oct;36(5):381-405. doi: 10.1007/s10928-009-9128-6. Epub 2009 Aug 21. J Pharmacokinet Pharmacodyn. 2009. PMID: 19697107 Free PMC article.
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema.
Zhang Y, Tortorici MA, Pawaskar D, Pragst I, Machnig T, Hutmacher M, Zuraw B, Cicardi M, Craig T, Longhurst H, Sidhu J. Zhang Y, et al. Among authors: pawaskar d. CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):158-165. doi: 10.1002/psp4.12271. Epub 2018 Jan 9. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 29316335 Free PMC article.
Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
Pawaskar D, Tortorici MA, Zuraw B, Craig T, Cicardi M, Longhurst H, Li HH, Lumry WR, Martinez-Saguer I, Jacobs J, Bernstein JA, Riedl MA, Katelaris CH, Keith PK, Feussner A, Sidhu J. Pawaskar D, et al. Clin Exp Allergy. 2018 Oct;48(10):1325-1332. doi: 10.1111/cea.13220. Epub 2018 Aug 26. Clin Exp Allergy. 2018. PMID: 29998524 Free article. Clinical Trial.
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygören-Pürsün E, Keith PK, Busse P, Feuersenger H, Pawaskar D, Jacobs I, Pragst I, Doyle MK. Craig T, et al. Among authors: pawaskar d. Lancet. 2022 Mar 5;399(10328):945-955. doi: 10.1016/S0140-6736(21)02225-X. Epub 2022 Feb 24. Lancet. 2022. PMID: 35219377
14 results